Related Experiment Video
Updated: Dec 15, 2025
Purification of Ubiquitinated p53 Proteins from Mammalian Cells
Published on: March 21, 2022
The Janus Face of p53-Targeting Ubiquitin Ligases
Qian Hao1, Yajie Chen2, Xiang Zhou1,3,4
1Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.
Abstract:
The tumor suppressor p53 prevents tumorigenesis and cancer progression by maintaining genomic stability and inducing cell growth arrest and apoptosis. Because of the extremely detrimental nature of wild-type p53, cancer cells usually mutate the TP53 gene in favor of their survival and propagation. Some of the mutant p53 proteins not only lose the wild-type activity, but also acquire oncogenic function, namely "gain-of-function", to promote cancer development. Growing evidence has revealed that various E3 ubiquitin ligases are able to target both wild-type and mutant p53 for degradation or inactivation, and thus play divergent roles leading to cancer cell survival or death in the context of different p53 status. In this essay, we reviewed the recent progress in our understanding of the p53-targeting E3 ubiquitin ligases, and discussed the potential clinical implications of these E3 ubiquitin ligases in cancer therapy.
Insights
The tumor suppressor p53 guards against cancer, but cancer cells often mutate TP53. E3 ubiquitin ligases target p53, influencing cancer cell fate and offering therapeutic potential.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- The tumor suppressor p53 (TP53) is crucial for preventing cancer by maintaining genomic stability and inducing apoptosis.
- Cancer cells frequently mutate TP53 to promote survival, with some mutants gaining oncogenic 'gain-of-function' properties.
- E3 ubiquitin ligases are key regulators of protein stability and function, including the degradation of p53.
Purpose of the Study:
- To review recent advancements in understanding E3 ubiquitin ligases that target p53.
- To discuss the dual roles of these ligases in either promoting cancer cell survival or death.
- To explore the potential clinical applications of p53-targeting E3 ubiquitin ligases in cancer therapy.
Main Methods:
- Literature review of recent research on p53-targeting E3 ubiquitin ligases.
- Analysis of studies investigating the mechanisms of p53 regulation by E3 ligases.
- Synthesis of information regarding the functional outcomes of E3 ligase activity on wild-type and mutant p53.
Main Results:
- E3 ubiquitin ligases differentially regulate both wild-type and mutant p53.
- These ligases can mediate p53 degradation or inactivation, impacting cancer progression.
- The specific role of an E3 ligase depends on the p53 status (wild-type vs. mutant) and cellular context.
Conclusions:
- E3 ubiquitin ligases play complex and context-dependent roles in cancer through p53 modulation.
- Targeting these E3 ligases represents a promising therapeutic strategy for various cancers.
- Further research into p53-E3 ligase interactions could uncover novel cancer treatment avenues.
Related Concept Videos
02:04Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
02:23Abnormal Proliferation
02:58Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
02:58Regulated Protein Degradation
01:13The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...